AlphaFold Accelerates Artificial Intelligence Powered Drug Discovery:
  Efficient Discovery of a Novel Cyclin-dependent Kinase 20 (CDK20) Small
  Molecule Inhibitor
  The AlphaFold computer program predicted protein structures for the whole
human genome, which has been considered as a remarkable breakthrough both in
artificial intelligence (AI) application and structural biology. Despite the
varying confidence level, these predicted structures still could significantly
contribute to structure-based drug design of novel targets, especially the ones
with no or limited structural information. In this work, we successfully
applied AlphaFold in our end-to-end AI-powered drug discovery engines
constituted of a biocomputational platform PandaOmics and a generative
chemistry platform Chemistry42, to identify a first-in-class hit molecule of a
novel target without an experimental structure starting from target selection
towards hit identification in a cost- and time-efficient manner. PandaOmics
provided the targets of interest and Chemistry42 generated the molecules based
on the AlphaFold predicted structure, and the selected molecules were
synthesized and tested in biological assays. Through this approach, we
identified a small molecule hit compound for CDK20 with a Kd value of 8.9 +/-
1.6 uM (n = 4) within 30 days from target selection and after only synthesizing
7 compounds. Based on the available data, the second round of AI-powered
compound generation was conducted and through which, a more potent hit
molecule, ISM042-2 048, was discovered with a Kd value of 210.0 +/- 42.4 nM (n
= 2), within 30 days and after synthesizing 6 compounds from the discovery of
the first hit ISM042-2-001. To the best of our knowledge, this is the first
reported small molecule targeting CDK20 and more importantly, this work is the
first demonstration of AlphaFold application in the hit identification process
in early drug discovery.
